Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 156293

HLA.

S B Moore
View original source ↗Export metadata ↓

Abstract

HLA typing in 1979 is more complex and more complete than in former years. The distribution of antigens in the HLA system and various methods of identifying them and of determining their structure and function are described. The usefulness of HLA typing in organ transplantation and paternity testing has been well established, and its place in blood component therapy is to some degree still conjectural. Detection of HLA antigens associated either positively or negatively with specific disease states has great importance for several reasons. From an academic point of view, these association may help to define pathogenetic mechanisms, and from a practical viewpoint, there is now good reason to believe that HLA typing may shortly be useful as a diagnostic and predictive tool. Further elucidation of the role of the HLA molecules in the immune response gives hope for better understanding of the immune and autoimmune disorders, which is surely the first step in defining rationally based therapeutic regimens.

Explore related subjects

Blood DonorsBlood TransfusionChromosome MappingGenesHLA AntigensHistocompatibility TestingHumansLymphocyte Culture Test, MixedMalePaternityTransplantation ImmunologyJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S B Moore. 1979. HLA.. https://pubmed.ncbi.nlm.nih.gov/156293/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

A comparison between one first generation and three second generation anti-HCV ELISAs: an investigation in high- and low-risk subjects in correlation with recombinant immunoblot assay and polymerase chain reaction.

One first generation assay (manufactured by Ortho, test I) and 3 second generation anti-HCV ELISAs (manufactured by Ortho, Abbott, and UBI, tests II-IV) were compared. Sera from 4 different sources were used: (1) intravenous drug-users (IVDUs, n = 50), (2) blood donors (n = 1055), (3) all clinical samples from one day of routine anti-HCV testing (n = 89), (4) hemodialysis patients previously found negative by test I but clinically suspected to have a HCV infection (n = 11). Confirmatory anti-HCV tests were carried out with a second generation recombinant immunoblot assay (RIBA II). In sera positive exclusively by test IV, one antibody consumption test (UBI HCV Neutralization EIA) and one further immunoblot assay (INNO-LIA HCV Ab) were used. PCR for HCV RNA was carried out on all hemodialysis patient sera and in the RIBA II positive blood donor sera. The second generation ELISAs discriminated 11 more positive samples than the first generation test (2 IVDUs, 5 blood donors, 4 clinical samples). The 9 sera from blood donors and clinical samples were all RIBA II positive or indeterminate. The second generation tests thus showed increased sensitivity. The second generation tests also showed increased specificity in that 4 samples that were positive by test I but negative by the second generation tests, were also negative by RIBA II. With few exceptions, all RIBA II-positive and most of the indeterminate samples were positive by the second generation ELISAs. With few exceptions, all the RIBA II-negative samples were negative by the second generation ELISAs. Eleven blood donor sera were positive by test IV exclusively where RIBA II and other supplementary assays were negative. The recently introduced second generation anti-HCV ELISAs were found to have a higher sensitivity than the first generation test. The tests also showed a good concordance with the exception of test IV in the group of blood donor sera.

Blood Donors↗